Recombinant Staphylococcus aureus Isopentenyl-diphosphate delta-isomerase (fni)

What is Isopentenyl-diphosphate delta-isomerase (fni) and what role does it play in S. aureus metabolism?

Isopentenyl-diphosphate delta-isomerase (IDI or fni) is an essential enzyme in the isoprenoid biosynthetic pathway of S. aureus. It catalyzes the reversible isomerization of isopentenyl diphosphate (IPP) to dimethylallyl diphosphate (DMAPP), a critical step in the biosynthesis of isoprenoids . This reaction is fundamental for producing precursors required for cell wall synthesis, electron transport chain components, and membrane maintenance. In S. aureus, IDI belongs to the Type II class (IDI-2), which differs significantly from the Type I enzymes found in humans and some other organisms. The S. aureus enzyme utilizes FMN as a cofactor and employs a distinct acid/base chemistry mechanism in its catalytic function .

How does the fni gene differ across clinical isolates of S. aureus, and what implications might this have for research?

Recent studies examining clinical isolates of S. aureus have demonstrated significant genetic diversity across strains . While specific data on fni gene variation is limited in the provided search results, the pattern of diversity observed in other virulence factors suggests that researchers should examine fni sequences across different clinical isolates. Variations in the gene could potentially affect enzyme activity, stability, or susceptibility to inhibitors. When working with recombinant fni, researchers should consider which strain variant they are using and how representative it is of the broader S. aureus population, particularly when developing targeted therapeutics or conducting comparative biochemical studies.

What expression systems yield optimal results for producing functional recombinant S. aureus fni protein?

Based on methodologies used for similar S. aureus proteins, E. coli-based expression systems typically provide the best balance of yield and functionality for recombinant S. aureus proteins. For optimal expression of functional fni, consider the following approach:

• Vector selection: pET-series vectors with T7 promoters are commonly effective

• Host strain: BL21(DE3) or Rosetta strains to address potential codon bias

• Affinity tags: N-terminal His6-tag with a TEV protease cleavage site facilitates purification while allowing tag removal

• Induction conditions: 0.1-0.5 mM IPTG at OD600 of 0.6-0.8

• Expression temperature: 16-20°C for 16-18 hours post-induction to enhance proper folding

• Media supplementation: Consider adding 10-50 μM FMN to growth media to facilitate cofactor incorporation during protein folding

This approach has been successfully applied to other S. aureus enzymes and should be adaptable for fni expression .

What purification strategies help maintain the enzymatic activity of recombinant S. aureus fni?

Maintaining enzymatic activity during purification requires careful attention to preserving the protein's structural integrity and cofactor binding. For S. aureus fni, which requires FMN as a cofactor, consider the following purification strategy:

• Buffer composition:

  • 50 mM Tris-HCl or HEPES buffer, pH 7.5-8.0

  • 150-300 mM NaCl to maintain solubility

  • 10-20% glycerol as a stabilizing agent

  • 1-5 mM β-mercaptoethanol or DTT to maintain reduced cysteine residues

  • 10-50 μM FMN supplementation in all buffers

• Purification steps:

  • Initial IMAC (immobilized metal affinity chromatography) for His-tagged protein

  • Size exclusion chromatography to remove aggregates and ensure homogeneity

  • Optional ion exchange chromatography as a polishing step

• Special considerations:

  • Perform all steps at 4°C to prevent protein denaturation

  • Protect from excessive light exposure to prevent FMN degradation

  • Analyze FMN content spectrophotometrically to ensure proper cofactor incorporation

  • Test enzymatic activity after each purification step to track activity retention

For long-term storage, flash-freeze purified enzyme in small aliquots with 25-50% glycerol and store at -80°C to minimize activity loss through freeze-thaw cycles.

What are the most reliable methods for measuring S. aureus fni enzymatic activity in vitro?

Several complementary approaches can be employed to measure S. aureus fni activity:

• Radiolabeled substrate assay:

  • Incubate enzyme with 14C-labeled IPP

  • Terminate reaction at various time points

  • Separate IPP and DMAPP by thin-layer chromatography or HPLC

  • Quantify product formation by scintillation counting

  • Advantages: Direct measurement of substrate-to-product conversion

• Enzyme-coupled spectrophotometric assay:

  • Link DMAPP production to NADPH oxidation through coupling enzymes

  • Monitor decrease in absorbance at 340 nm

  • Calculate reaction rates based on NADPH consumption

  • Advantages: Continuous measurement, no radioactivity required

• Enzyme-coupled fluorescence assay:

  • Similar to the approach used for farnesyl diphosphate synthase

  • Couple DMAPP formation to subsequent enzymatic reactions

  • Monitor changes in fluorescence of a suitable reporter molecule

  • Advantages: Higher sensitivity than spectrophotometric methods

For comprehensive characterization, researchers should employ at least two different methods to validate their findings.

How can I investigate the acid/base chemistry mechanism of S. aureus fni through experimental approaches?

Investigating the acid/base chemistry of S. aureus fni requires a multifaceted approach:

• Site-directed mutagenesis:

  • Identify putative catalytic residues through sequence alignment with characterized Type II IDIs

  • Create alanine substitutions to eliminate function

  • Create conservative substitutions (e.g., His→Asn, Asp→Asn) to test specific catalytic roles

  • Perform comprehensive kinetic analysis on each mutant

• pH-rate profile analysis:

  • Determine enzyme activity across pH range 5.0-9.0

  • Plot log(kcat) and log(kcat/KM) versus pH

  • Identify inflection points corresponding to pKa values of catalytic residues

  • Compare wild-type profiles with those of key mutants

• Solvent kinetic isotope effects:

  • Compare reaction rates in H2O versus D2O

  • Calculate primary kinetic isotope effects (KIEs)

  • Identify rate-limiting proton transfer steps

  • Perform proton inventory studies with varying H2O/D2O ratios

• Structural studies:

  • Obtain crystal structures of enzyme with substrate analogs or inhibitors

  • Identify active site architecture and potential proton relay networks

  • Use molecular dynamics simulations to model proton transfer pathways

This integrated approach has been successful in elucidating the acid/base chemistry of Type II isopentenyl diphosphate/dimethylallyl diphosphate isomerase from S. aureus in previous studies .

Could S. aureus fni serve as a potential vaccine antigen, and what experimental approach would evaluate this possibility?

Evaluating S. aureus fni as a potential vaccine antigen requires consideration of several factors in the context of S. aureus vaccine development challenges:

• Suitability assessment:

  • Expression level analysis during infection

  • Accessibility to immune system (cytoplasmic enzymes may be less accessible)

  • Conservation across clinical isolates

  • Pre-existing antibody levels in human populations

• Experimental evaluation pathway:

  • Recombinant protein production with appropriate adjuvants

  • Animal immunization studies

  • Functional antibody assessment

  • Protection evaluation in appropriate challenge models

• Integration with multicomponent approaches:

  • Recent S. aureus vaccine development has focused on multicomponent strategies targeting multiple virulence mechanisms

  • Fni could potentially complement existing vaccine candidates like capsular polysaccharides, ClfA, and MntC

  • Evaluation within the context of a multicomponent formulation would be critical

• Expected challenges:

  • As a cytoplasmic enzyme, antibody accessibility may be limited

  • Functionality of anti-fni antibodies would need careful assessment

  • Cross-reactivity with human IDI would need evaluation

The comprehensive S. aureus vaccine development approach described in search result provides a valuable framework for evaluating new antigens, emphasizing the need for functional antibodies and targeting multiple virulence mechanisms simultaneously.

What computational approaches can predict inhibitor binding to S. aureus fni based on structural data?

Advanced computational methods can accelerate the discovery of S. aureus fni inhibitors:

• Homology modeling and refinement:

  • If crystal structure is unavailable, build homology model based on related Type II IDIs

  • Refine with molecular dynamics simulations

  • Validate model with known biochemical data

• Virtual screening workflows:

  • Structure-based virtual screening of compound libraries

  • Pharmacophore-based screening focusing on FMN binding pocket and substrate binding site

  • Molecular docking with flexible residue treatment

  • Consensus scoring using multiple algorithms

• Molecular dynamics-based approaches:

  • Long-timescale MD simulations to identify transient binding pockets

  • Binding free energy calculations using methods like MM/PBSA or FEP

  • Identification of water-mediated interactions critical for binding

• Machine learning integration:

  • Train models on known enzyme inhibitors

  • Generate QSAR models for activity prediction

  • Develop deep learning approaches for binding affinity prediction

• Workflow validation:

  • Retrospective validation using known inhibitors

  • Binding site mutation analysis

  • Experimental validation of top-ranked compounds

Such computational approaches can significantly accelerate the discovery process by prioritizing compounds for experimental testing, potentially leading to novel antibiotics targeting this essential S. aureus enzyme.

How can CRISPR-Cas9 technology be applied to study the role of fni in S. aureus pathogenesis?

CRISPR-Cas9 technology offers powerful approaches to investigate fni function in S. aureus:

• Gene editing strategies:

  • Create precise point mutations to study specific residues

  • Generate deletion mutants for functional studies

  • Introduce fluorescent protein fusions for localization studies

• CRISPR interference (CRISPRi) for conditional knockdown:

  • Design guide RNAs targeting fni promoter or coding sequence

  • Express catalytically inactive Cas9 (dCas9) for transcriptional repression

  • Create inducible systems for temporal control of gene silencing

  • Examine effects on growth, metabolism, and virulence

• CRISPR activation (CRISPRa) for overexpression studies:

  • Target transcriptional activators to the fni promoter

  • Assess metabolic and phenotypic consequences of overexpression

  • Identify potential regulatory feedback mechanisms

• Library-based approaches:

  • Create guide RNA libraries targeting genes throughout the genome

  • Screen for genetic interactions with fni

  • Identify synthetic lethal relationships that could inform combination therapy approaches

• In vivo applications:

  • Develop systems for conditional fni regulation during infection

  • Study the temporal requirements for fni activity at different infection stages

  • Identify host niches or infection phases where fni is most critical

These CRISPR-based approaches can provide unprecedented insights into fni function in different contexts, potentially revealing new strategies for therapeutic intervention targeting S. aureus isoprenoid metabolism.

What factors commonly affect the reproducibility of S. aureus fni enzymatic assays, and how can they be controlled?

Several factors can impact reproducibility in fni enzymatic assays:

• Cofactor considerations:

  • FMN oxidation state variability

  • Solution: Standardize FMN preparation, protect from light, and verify spectrophotometrically

  • Control: Include defined FMN:protein ratios in all assays (typically 1:1 molar ratio)

• Substrate quality issues:

  • IPP degradation during storage

  • Solution: Prepare fresh substrate solutions or store in small aliquots at -80°C

  • Control: Include substrate stability controls in each assay series

• Enzyme stability variables:

  • Batch-to-batch variation in specific activity

  • Solution: Develop rigorous quality control criteria for enzyme preparations

  • Control: Include standard reference preparations in assays

• Reaction condition inconsistencies:

  • Temperature fluctuations during assay

  • pH variations among buffer preparations

  • Solution: Use temperature-controlled instruments and prepare fresh buffers

  • Control: Include internal standards in each assay plate or run

• Data analysis variations:

  • Different methods for calculating initial rates

  • Solution: Establish standardized analysis protocols

  • Control: Use automated analysis scripts to ensure consistent data processing

Implementing these controls can significantly improve assay reproducibility across different laboratories and experiments.

When studying S. aureus fni as a potential antibiotic target, what experimental controls are essential to validate the specificity of observed effects?

Rigorous experimental controls are crucial when evaluating fni as an antibiotic target:

• Target validation controls:

  • Inducible knockdown or conditional mutants of fni to confirm phenotype

  • Genetic complementation studies with wild-type fni to rescue phenotypes

  • Point mutations in catalytic residues to distinguish enzymatic and structural roles

• Inhibitor specificity controls:

  • Testing against human Type I IDI to assess selectivity

  • Evaluation against unrelated enzymes to confirm target specificity

  • Metabolomic analysis to verify expected pathway perturbations

  • Testing inactive structural analogs of inhibitors as negative controls

• Mechanism of action verification:

  • Enzyme inhibition assays correlating with cellular effects

  • Resistant mutant generation and characterization

  • Target engagement studies in intact bacteria

  • Metabolite supplementation to bypass metabolic blocks

• Phenotypic effect controls:

  • Comparison with known antibiotics of different mechanisms

  • Time-kill kinetics to distinguish bacteriostatic from bactericidal effects

  • Post-antibiotic effect determination

  • Biofilm versus planktonic state comparisons

• In vivo relevance controls:

  • Pharmacokinetic/pharmacodynamic correlation studies

  • Multiple infection models with different readouts

  • Comparison of effects in standard laboratory and clinical isolates

These controls help ensure that observed antimicrobial effects are specifically due to fni inhibition rather than off-target actions or general toxicity mechanisms.

How might single-cell techniques advance our understanding of fni function in heterogeneous S. aureus populations?

Single-cell approaches offer unique insights into fni function that population-level studies cannot provide:

• Single-cell transcriptomics:

  • Reveal expression heterogeneity of fni within bacterial populations

  • Identify co-expression networks linking fni to other metabolic or virulence genes

  • Discover subpopulations with distinct isoprenoid metabolism profiles

• Microfluidic techniques:

  • Track individual bacterial responses to fni inhibition over time

  • Correlate fni expression with growth rate, division timing, and morphology

  • Observe recovery dynamics after transient inhibition

• Single-cell protein analysis:

  • Quantify fni protein levels using targeted proteomics approaches

  • Detect post-translational modifications affecting enzyme activity

  • Analyze protein-protein interactions at the single-cell level

• Fluorescent reporters and biosensors:

  • Create translational fusions to monitor fni expression dynamics

  • Develop FRET-based sensors for enzyme activity

  • Design biosensors for IPP/DMAPP ratio monitoring in live cells

• Time-lapse microscopy:

  • Visualize effects of fni inhibition on cell division and morphology

  • Track bacterial cell fate decisions under metabolic stress

  • Correlate enzyme activity with phenotypic variability

These single-cell approaches would help explain how isoprenoid metabolism heterogeneity might contribute to phenomena like antibiotic tolerance, persister cell formation, and population-level resistance to environmental stresses.

What opportunities exist for integrating fni inhibition with other therapeutic approaches against multidrug-resistant S. aureus?

Innovative combination strategies could enhance the therapeutic potential of fni inhibition:

• Synergistic antibiotic combinations:

  • Screen for potentiation effects between fni inhibitors and existing antibiotics

  • Focus on agents affecting cell wall (e.g., β-lactams) or membrane integrity

  • Identify combinations that reduce the emergence of resistance

• Anti-virulence approach integration:

  • Combine fni inhibition with inhibitors of toxin production

  • Target multiple metabolic pathways simultaneously

  • Develop dual-action molecules affecting both fni and virulence factor expression

• Immunomodulatory combinations:

  • Pair with agents that enhance host immune response

  • Combine with vaccine-induced immunity for enhanced clearance

  • Explore adjuvant therapies that complement metabolic inhibition

• Targeted delivery strategies:

  • Develop nanoparticle formulations for improved delivery of fni inhibitors

  • Create prodrug approaches for selective activation in S. aureus

  • Design bacteriophage-based delivery of CRISPR systems targeting fni

• Biofilm-focused approaches:

  • Combine with biofilm dispersal agents for enhanced penetration

  • Develop formulations effective against metabolically inactive biofilm populations

  • Target biofilm-specific metabolic adaptations involving isoprenoid pathways

• Resistance prevention strategies:

  • Implement cycling or sequential therapy protocols

  • Design multi-targeting inhibitors affecting multiple steps in isoprenoid biosynthesis

  • Develop collateral sensitivity approaches where resistance to one agent increases sensitivity to another

Such integrated approaches could address the limitations of single-target therapeutics and provide more robust options for treating multidrug-resistant S. aureus infections.